{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06399757",
            "orgStudyIdInfo": {
                "id": "AP10CP01"
            },
            "organization": {
                "fullName": "Apollo Therapeutics Ltd",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors",
            "officialTitle": "A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-investigate-apl-in-adults-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-01",
            "studyFirstSubmitQcDate": "2024-05-01",
            "studyFirstPostDateStruct": {
                "date": "2024-05-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Apollo Therapeutics Ltd",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC)."
        },
        "conditionsModule": {
            "conditions": [
                "Colorectal Cancer",
                "Cholangiocarcinoma",
                "Appendiceal Adenocarcinoma",
                "Pancreatic Adenocarcinoma",
                "Gastric Adenocarcinoma",
                "Endometrial Adenocarcinoma",
                "Triple Negative Breast Cancer",
                "Ovarian Cancer",
                "Prostate Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1: Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Dose escalation with increasing dose levels of APL-5125 to identify Recommended Phase 2 Dose.\n\nPossibility to expand into select populations",
                    "interventionNames": [
                        "Drug: APL-5125"
                    ]
                },
                {
                    "label": "Phase 2: Dose Expansion/Optimization",
                    "type": "EXPERIMENTAL",
                    "description": "Up to 2 dose levels of APL-5125 in a selected population",
                    "interventionNames": [
                        "Drug: APL-5125"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "APL-5125",
                    "description": "APL-5125 is an oral drug (capsule) taken daily in 28-day cycles",
                    "armGroupLabels": [
                        "Phase 1: Dose Escalation",
                        "Phase 2: Dose Expansion/Optimization"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment Emergent Adverse Events [Safety] (Phase 1)",
                    "description": "Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, electrocardiogram results.",
                    "timeFrame": "Through study completion, approximately one year"
                },
                {
                    "measure": "Incidence of dose limiting toxicities [Tolerability] (Phase 1)",
                    "description": "Evaluation of tolerability parameters including dose limiting toxicities as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs and electrocardiogram results",
                    "timeFrame": "Cycle 1 Day 1 to Cycle 2 Day 1 (a cycle is 28 days)"
                },
                {
                    "measure": "Estimate the maximum tolerated dose (MTD) of APL-5125 in participants with selected advanced solid tumors (Phase 1)",
                    "timeFrame": "Cycle 1 Day 1 to Cycle 2 Day 1 (a cycle is 28 days)"
                },
                {
                    "measure": "Determine Recommended Phase 2 Dose (RP2D) levels of APL-5125 in participants with selected advanced solid tumors (Phase 1)",
                    "timeFrame": "Approximately one year"
                },
                {
                    "measure": "Assess the anti-tumor activity of APL-5125 in patients with Colorectal carcinoma (Phase 2)",
                    "description": "Response is assessed per RECIST version 1.1 criteria",
                    "timeFrame": "Response is assessed every 8 weeks; after one year of treatment, response is assessed every 12 weeks. (Assessed for up to 2 years.)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Assess the preliminary anti-tumor activity of APL-5125 in colorectal carcinoma patients (Phase 1)",
                    "description": "Response is assessed per RECIST version 1.1 criteria",
                    "timeFrame": "Response is assessed every 8 weeks; after one year of treatment, response is assessed every 12 weeks. (Assessed for up to 2 years.)"
                },
                {
                    "measure": "Assess the pharmacokinetics (PK) of APL-5125 (Phase 1)",
                    "description": "Evaluate PK parameters: oral clearance",
                    "timeFrame": "On days 1, 2, 4, 8, 15 of cycle 1, and on day 1 of cycle 2 and cycle 3 (a cycle is 28 days)."
                },
                {
                    "measure": "Assess the pharmacokinetics (PK) of APL-5125 (Phase 1)",
                    "description": "Evaluate PK parameters: volume of distribution",
                    "timeFrame": "On days 1, 2 ,4, 8, 15 of cycle 1, and on day 1 of cycle 2 and cycle 3 (a cycle is 28 days)."
                },
                {
                    "measure": "Further assess the anti-tumor activity of APL-5125 (Phase 2)",
                    "description": "Response is assessed per RECIST version 1.1 criteria",
                    "timeFrame": "Response is assessed every 8 weeks; after one year of treatment, response is assessed every 12 weeks. (Assessed for up to 2 years.)"
                },
                {
                    "measure": "Incidence of treatment emergent adverse events [Further Safety] (Phase 2)",
                    "description": "Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, electrocardiogram results",
                    "timeFrame": "Through study completion (approximately 2 years)"
                },
                {
                    "measure": "Further assess the PK of APL-5125 (Phase 2)",
                    "description": "Evaluate PK parameters: oral clearance",
                    "timeFrame": "On days 1, 2, 4, 8, 15 of cycle 1, and on day 1 of cycle 2 and cycle 3 (a cycle is 28 days)."
                },
                {
                    "measure": "Further assess the PK of APL-5125 (Phase 2)",
                    "description": "Evaluate PK parameters: volume of distribution",
                    "timeFrame": "On days 1, 2, 4, 8, 15 of cycle 1, and on day 1 of cycle 2 and cycle 3 (a cycle is 28 days)."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years or older\n* Phase 1: Histologically confirmed locally advanced, inoperable, or metastatic tumor; Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma.\n* For Phase 1 sub-studies: Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer\n* Phase 2: Colorectal carcinoma\n* No available standard of care therapy or participant is ineligible for standard of care therapy, except in CRC tumor type in which participant must have previously received all the following therapeutic agents:\n\n  * fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy\n  * an anti-VEGF therapy\n  * if wt-RAS (wt-KRAS and wt-NRAS), an anti-EGFR therapy\n* Eastern Cooperative Oncology Group (ECOG) \u22641\n* Body Weight \u226540 kg.\n* Female participants of childbearing potential must have negative serum pregnancy test at screening; must not plan to become pregnant or have ova harvested or breastfeed while on study; must be willing to use specific contraception or avoid intercourse\n* Male participants must be willing to use specific contraception and not plan to impregnate a female partner or donate sperm while on study\n* Participant must be willing and able to provide written informed consent and to comply with the requirements of the trial\n\nExclusion Criteria:\n\n* Certain medical conditions such as: active brain metastases, carcinomatous meningitis, unstable angina pectoris, myocardial infarction or clinically significant ventricular arrhythmias, symptomatic congestive heart failure, uncontrolled active infection, history of significant hemorrhage within 4 weeks of the first dose date, intestinal disease or major gastric surgery, arterial thrombosis within 6 months of screening\n* Certain prior therapies such as: anti-cancer treatment within 2 weeks of screening, prior radiotherapy within 14 days before screening, active anti-coagulation therapy, over the counter or prescription medications within 14 days or 5 half-lives prior to cycle 1 day 1, herbal medicines and supplements within 14 days\n* Major surgery within 1 month of screening\n* Hemoglobin \\< 9.0 g/dL\n* Absolute neutrophil count \\< 1.5 x 10\\^9/L\n* Platelet count \\< 100 x 10\\^9/L\n* Hepatic function:\n\n  1. Aspartate aminotransferase and/or alanine aminotransferase (ALT) \\>3 \u00d7 upper limit of normal (ULN) (\\>5 x ULN for subjects with liver metastases)\n  2. Total bilirubin \\>1.5 \u00d7 ULN (except participants with Gilbert's syndrome).\n  3. Albumin \\< 3 g/dL\n* Calculated or measured creatinine clearance of \\<60 mL/minute calculated using the formula of Cockcroft and Gault (\\[140 - Age\\] \u00d7 Mass \\[kg\\] / \\[72 \u00d7 serum creatinine mg/dL\\]). Multiply result by 0.85 if female.\n* Fridericia's corrected QT interval (QTcF) \\>470 msec or a family history of Long QT Syndrome.\n* Cardiac function: Echocardiogram (or MUGA) showing Left Ventricular Ejection Fraction (LVEF) \\<45% at rest\n* Infectious diseases: positive for HIV (unless controlled with active retroviral therapy), hepatitis B and hepatitis C",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Apollo Therapeutics",
                    "role": "CONTACT",
                    "phone": "781-479-2267",
                    "email": "AP10@apollotx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Daniela Pignataro, MD",
                    "affiliation": "Apollo Therapeutics Ltd",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Apollo Investigative Site",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Apollo Investigative Site",
                    "status": "RECRUITING",
                    "city": "Huntersville",
                    "state": "North Carolina",
                    "zip": "28078",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.41069,
                        "lon": -80.84285
                    }
                },
                {
                    "facility": "Apollo Investigative Site",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000064726",
                    "term": "Triple Negative Breast Neoplasms"
                },
                {
                    "id": "D000018281",
                    "term": "Cholangiocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M30373",
                    "name": "Triple Negative Breast Neoplasms",
                    "asFound": "Triple Negative Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M20426",
                    "name": "Cholangiocarcinoma",
                    "asFound": "Cholangiocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T755",
                    "name": "Bile Duct Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T200",
                    "name": "Adenocarcinoma of the Appendix",
                    "asFound": "Appendiceal Adenocarcinoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}